FDA Panel Rejects New Oral Testosterone Replacement Drug
Article Title: FDA Panel Rejects New Oral Testosterone Replacement Drug
Author: Larry Hand
Date of Publication: September 18, 2014
A combined US Food and Drug Administration (FDA) advisory committee has voted against recommending approval of oral testosterone undecanoate (TU) gel capsules as testosterone-replacement therapy (TRT).
In a joint session today of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, panelists voted 12 to 8, with 1 abstention, that there is insufficient evidence to conclude that the testosterone prodrug is effective. They voted 18 to 3 that the overall benefit/risk profile was not acceptable to support approval.
